Heart failure epidemiology and treatment in primary care: a retrospective cross‐sectional study

Abstract

Aims Heart failure is one of the leading causes of morbidity and mortality worldwide, but little is known on heart failure epidemiology and treatment in primary care. This study described patients with heart failure treated by general practitioners, with focus on drug prescriptions and especially on the only specific treatment for heart failure with reduced ejection fraction, namely sacubitril/valsartan. Methods and results This was a retrospective cross‐sectional study using data from an electronic medical record database of Swiss general practitioners from 2016 to 2019. Multilevel logistic regression was used to find determinants of sacubitril/valsartan prescription; odds ratios (ORs) and 95% confidence intervals (CIs) were reported. We identified 1288 heart failure patients (48.5% women; age: median 85 years, interquartile range 77–90 years) by means of diagnosis code, representing 0.5% of patients consulting a general practitioner during the observation period. About 73.6% received a renin–angiotensin–aldosterone system inhibitor, 67.8% a beta‐blocker, 34.6% a calcium channel blocker, 86.1% a diuretic, and 40.1% another cardiac drug. Sacubitril/valsartan was prescribed in 6% predominantly male patients (OR 2.10, CI 1.25–3.84), of younger age (OR 0.59 per increase in 10 years, CI 0.49–0.71), with diabetes mellitus (OR 1.76, CI 1.07–2.90). The recommended starting dose for sacubitril/valsartan was achieved in 67.1% and the target dose in 28.6% of patients. Conclusions Prevalence of heart failure among patients treated by general practitioners was low. Considering the disease burden and association with multimorbidity, awareness of heart failure in primary care should be increased, with the aim to optimize heart failure therapy.

Adding a “Notch” to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach

“…These conditions cause the dysregulation of cellular and molecular signaling cascades leading to cardiomyocytes apoptosis, ultimately causing myocardial hypertrophy and fibrosis, all contributing to ventricular wall thickening and stiffening that ultimately compromise the heart contractile function ( Cohn et al, 2000 ; Ferrari and Rizzo, 2014 ). Even in the presence of novel therapeutics treatments, the morbidity and mortality due to HF remain high ( Rachamin et al, 2021 ).…”

Preditores de prognóstico da insuficiência cardíaca através de exames de imagem

“…Estima-se que o risco de um indivíduo desenvolver o quadro de insuficiência cardíaca ao longo da vida seja de 20%. A IC é considerada uma pandemia global com cerca de 26 milhões de pessoas afetadas em todo o mundo e que se destaca pela elevada mortalidade e morbidade (Ambrosy et al, 2014;Rachamin et al, 2020;Rohde et al, 2018).…”

Congestive Heart Failure: Diagnosis and Management in Primary Health Care

“…Heart failure disease has been one of the major chronic cardiovascular diseases that cause morbidity, mortality, and hospitalization of all cardiac patients. Heart failure has a significantly increased lifetime risk of development is about 20% [1,2]. Other studies estimated the overall lifetime risk percent according to gender, where men 33% are higher in developing heart failure than women 28% [3,4].…”